| Year |
Citation |
Score |
| 2023 |
Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nature Medicine. PMID 37865722 DOI: 10.1038/s41591-023-02605-z |
0.307 |
|
| 2023 |
Spisak S, Tisza V, Nuzzo PV, Seo JH, Pataki B, Ribli D, Sztupinszki Z, Bell C, Rohanizadegan M, Stillman DR, Alaiwi SA, Bartels AH, Papp M, Shetty A, Abbasi F, ... ... Baca S, et al. Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nature Communications. 14: 6623. PMID 37857693 DOI: 10.1038/s41467-023-42515-9 |
0.302 |
|
| 2023 |
Spisak S, Tisza V, Nuzzo PV, Seo JH, Pataki B, Ribli D, Sztupinszki Z, Bell C, Rohanizadegan M, Stillman DR, Alaiwi SA, Bartels AB, Papp M, Shetty A, Abbasi F, ... ... Baca S, et al. A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nature Communications. 14: 5118. PMID 37612286 DOI: 10.1038/s41467-023-40616-z |
0.379 |
|
| 2023 |
Moon I, LoPiccolo J, Baca SC, Sholl LM, Kehl KL, Hassett MJ, Liu D, Schrag D, Gusev A. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nature Medicine. 29: 2057-2067. PMID 37550415 DOI: 10.1038/s41591-023-02482-6 |
0.354 |
|
| 2023 |
Gusev A, Moon I, LoPiccolo J, Baca S, Sholl L, Kehl K, Hassett M, Liu D, Schrag D. Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients. Research Square. PMID 36711812 DOI: 10.21203/rs.3.rs-2450090/v1 |
0.361 |
|
| 2022 |
Kneppers J, Severson TM, Siefert JC, Schol P, Joosten SEP, Yu IPL, Huang CF, Morova T, Altıntaş UB, Giambartolomei C, Seo JH, Baca SC, Carneiro I, Emberly E, Pasaniuc B, et al. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential. Nature Communications. 13: 7367. PMID 36450752 DOI: 10.1038/s41467-022-35135-2 |
0.401 |
|
| 2022 |
De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, ... ... Baca SC, et al. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Cancer Discovery. PMID 36399432 DOI: 10.1158/2159-8290.CD-22-0692 |
0.456 |
|
| 2022 |
Shi X, Day A, Bergom HE, Tape S, Baca SC, Sychev ZE, Larson G, Bozicevich A, Drake JM, Zorko N, Wang J, Ryan CJ, Antonarakis ES, Hwang J. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. Npj Precision Oncology. 6: 80. PMID 36323882 DOI: 10.1038/s41698-022-00323-2 |
0.308 |
|
| 2022 |
Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, Ding Y, Schwarz T, Huang CF, Anderson J, Fay AP, Kalita C, Groha S, Pomerantz MM, Wang V, et al. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nature Genetics. PMID 36071171 DOI: 10.1038/s41588-022-01168-y |
0.384 |
|
| 2022 |
Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, ... Baca SC, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. Cancer Discovery. PMID 35754340 DOI: 10.1158/2159-8290.CD-21-0576 |
0.421 |
|
| 2022 |
Berchuck JE, Adib E, Abou Alaiwi S, Dash AK, Shin JN, Lowder D, McColl C, Castro P, Carelli R, Benedetti E, Deng J, Robertson M, Baca SC, Bell C, McClure HM, et al. The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response. Cancer Research. PMID 35731919 DOI: 10.1158/0008-5472.CAN-21-3552 |
0.362 |
|
| 2022 |
Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, et al. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor targeting therapies. Elife. 11. PMID 35550030 DOI: 10.7554/eLife.73223 |
0.51 |
|
| 2022 |
Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, Davies A, Zoubeidi A. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nature Communications. 13: 2282. PMID 35477723 DOI: 10.1038/s41467-022-29963-5 |
0.302 |
|
| 2022 |
Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, Corey E, Chandel NS, Catalona WJ, Yang X, Freedman ML, et al. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature Genetics. PMID 35468964 DOI: 10.1038/s41588-022-01045-8 |
0.416 |
|
| 2022 |
Tang S, Sethunath V, Metaferia NY, Nogueira MF, Gallant DS, Garner ER, Lairson LA, Penney CM, Li J, Gelbard MK, Alaiwi SA, Seo JH, Hwang JH, Strathdee CA, Baca SC, et al. A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Reports. 38: 110417. PMID 35196489 DOI: 10.1016/j.celrep.2022.110417 |
0.421 |
|
| 2021 |
Berchuck JE, Baca SC, McClure HM, Korthauer K, Tsai HK, Vitale Nuzzo P, Kelleher KM, He M, Steinharter JA, Zacharia S, Spisak S, Seo JH, Conteduca V, Elemento O, Auh J, et al. Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34907080 DOI: 10.1158/1078-0432.CCR-21-3762 |
0.372 |
|
| 2021 |
Giambartolomei C, Seo JH, Schwarz T, Freund MK, Johnson RD, Spisak S, Baca SC, Gusev A, Mancuso N, Pasaniuc B, Freedman ML. H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility. American Journal of Human Genetics. PMID 34822763 DOI: 10.1016/j.ajhg.2021.11.007 |
0.404 |
|
| 2021 |
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, ... ... Baca S, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications. 12: 5775. PMID 34599169 DOI: 10.1038/s41467-021-26042-z |
0.589 |
|
| 2021 |
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer. 2: 444-456. PMID 33899001 DOI: 10.1038/s43018-021-00185-w |
0.372 |
|
| 2021 |
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications. 12: 1979. PMID 33785741 DOI: 10.1038/s41467-021-22139-7 |
0.406 |
|
| 2021 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, ... ... Baca SC, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications. 12: 808. PMID 33547292 DOI: 10.1038/s41467-021-21068-9 |
0.509 |
|
| 2020 |
Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, Gusev A, Korthauer KD, Severson TM, Ha G, Viswanathan SR, Seo JH, Nguyen HM, Zhang B, Pasaniuc B, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics. PMID 32690948 DOI: 10.1038/S41588-020-0664-8 |
0.485 |
|
| 2020 |
Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Steinharter J, Bouchard G, Curran CR, Pan W, Baca SC, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nature Medicine. PMID 32572266 DOI: 10.1038/S41591-020-0933-1 |
0.339 |
|
| 2020 |
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866 |
0.615 |
|
| 2020 |
Nuzzo PV, Berchuck JE, Spisak S, Korthauer K, Nassar A, Abou Alaiwi S, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Baca S, Lee GM, Chang SL, Waikar S, Sonpavde G, et al. Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Journal of Clinical Oncology. 38: 728-728. DOI: 10.1200/Jco.2020.38.6_Suppl.728 |
0.34 |
|
| 2020 |
Nuzzo PV, Spisak S, Berchuck JE, Baca S, Korthauer K, Nassar A, Alaiwi SA, Bakouny Z, Flippot R, Steinharter JA, Curran C, Lee GM, Waikar S, Pomerantz M, Carvalho DD, et al. Detection of urothelial carcinoma using plasma cell-free methylated DNA. Journal of Clinical Oncology. 38: 5046-5046. DOI: 10.1200/Jco.2020.38.15_Suppl.5046 |
0.307 |
|
| 2019 |
Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, et al. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. Cancer Discovery. PMID 31466944 DOI: 10.1158/2159-8290.Cd-19-0189 |
0.468 |
|
| 2019 |
Alaiwi SA, Nassar A, Bakouny ZE, Berchuck JE, Nuzzo P, Flippot R, Flaifel A, Steinharter JA, Baca S, Margolis C, Vokes N, Du H, Shukla SA, Braun DA, Signoretti S, et al. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 37: 103-103. DOI: 10.1200/Jco.2019.37.15_Suppl.103 |
0.402 |
|
| 2019 |
Sheahan A, Morel K, Burkhart D, Baca S, Labbè D, Roehle K, Calagua C, Ye H, Galbo P, Panja S, Mitrofanova A, Hamid A, Kibel A, Choudhury A, Pomerantz M, et al. Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B006 |
0.482 |
|
| 2017 |
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology. 18: 80. PMID 28464947 DOI: 10.1186/S13059-017-1183-5 |
0.542 |
|
| 2014 |
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: E5564-73. PMID 25512523 DOI: 10.1073/Pnas.1419260111 |
0.709 |
|
| 2014 |
Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Prive GG, Carr SA, Garraway LA. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (New York, N.Y.). 346: 85-89. PMID 25278611 DOI: 10.1126/Science.1250255 |
0.637 |
|
| 2014 |
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology. 15: 439. PMID 25160065 DOI: 10.1186/S13059-014-0439-6 |
0.652 |
|
| 2014 |
Kiezun A, Perry J, Tonzi P, Allen EV, Carter SL, Baca S, Bhatt A, Lawrence M, Walensky L, Wagle N, Mora J, deTorres C, Lavarino C, Velasco-Hidalgo L, Cardenas-Cardos R, et al. Abstract A41: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A41 |
0.707 |
|
| 2013 |
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, ... ... Baca S, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499: 214-8. PMID 23770567 DOI: 10.1038/Nature12213 |
0.619 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, et al. Punctuated evolution of prostate cancer genomes. Cell. 153: 666-77. PMID 23622249 DOI: 10.1016/J.Cell.2013.03.021 |
0.729 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, et al. Abstract 4601: Punctuated evolution of prostate cancer genomes. Cancer Research. 73: 4601-4601. DOI: 10.1158/1538-7445.Am2013-4601 |
0.691 |
|
| 2013 |
Prandi D, Baca SC, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, et al. Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. Cancer Research. 73: 4017-4017. DOI: 10.1158/1538-7445.Am2013-4017 |
0.656 |
|
| 2013 |
Barbieri C, Blattner M, Xu L, Demichelis F, Baca S, Lawrence M, Boysen G, Theurillat J, Tewari A, Zhou P, Garraway L, Rubin M. 200 DEFINING THE MECHANISTIC BASIS OF SPOP MUTATIONS IN PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1580 |
0.632 |
|
| 2012 |
Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Research. 72: 4383-93. PMID 22751462 DOI: 10.1158/0008-5472.Can-11-3893 |
0.476 |
|
| 2012 |
Baca SC, Garraway LA. The genomic landscape of prostate cancer. Frontiers in Endocrinology. 3: 69. PMID 22649426 DOI: 10.3389/Fendo.2012.00069 |
0.694 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. 44: 685-9. PMID 22610119 DOI: 10.1038/Ng.2279 |
0.718 |
|
| 2012 |
Barbieri C, Baca S, Demichelis F, Lawrence M, Blattner M, Theurillat J, Boysen G, Stojanov P, Van Allen E, Stransky N, Nickerson E, Park K, Kitabayashi N, MacDonald T, Vuong T, et al. 1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1661 |
0.623 |
|
| Show low-probability matches. |